Azucena
Esparís Ogando
Publicaciones en las que colabora con Azucena Esparís Ogando (35)
2024
-
ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression
International Journal of Molecular Sciences, Vol. 25, Núm. 6
2023
-
Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications
Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257
2022
-
ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology
Cancers, Vol. 14, Núm. 14
2021
-
Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer
npj Precision Oncology, Vol. 5, Núm. 1
2020
-
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer
Cancer Letters, Vol. 491, pp. 50-59
2019
-
A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
Frontiers in Immunology, Vol. 10
-
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1
-
MEK5 promotes lung adenocarcinoma
The European respiratory journal
2017
-
ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA
Oncogene, Vol. 36, Núm. 12, pp. 1733-1744
2016
-
Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies
Oncotarget, Vol. 7, Núm. 29, pp. 45042-45051
-
Targeting the EGF/HER ligand-receptor system in cancer
Current Pharmaceutical Design, Vol. 22, Núm. 39, pp. 5887-5898
2015
-
The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma
Gut, Vol. 64, Núm. 9, pp. 1454-1465
2014
-
Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer
Oncogene, Vol. 33, Núm. 2, pp. 148-156
-
Therapeutic potential of ERK5 targeting in triple negative breast cancer
Oncotarget, Vol. 5, Núm. 22, pp. 11308-11318
2013
-
Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue
Stem Cells, Vol. 31, Núm. 6, pp. 1075-1085
-
ERK5/BMK1 is a novel target of the tumor suppressor VHL: Implication in clear cell renal carcinoma
Neoplasia (United States), Vol. 15, Núm. 6, pp. 649-659
-
Potent antimyeloma activity of a novel ERK5/CDK inhibitor
Clinical Cancer Research, Vol. 19, Núm. 10, pp. 2677-2687
2009
-
ERK2, but not ERK1, mediates acquired and "De novo" resistance to imatinib mesylate: Implication for CML therapy
PLoS ONE, Vol. 4, Núm. 7
-
Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as potential therapeutic target
PLoS ONE, Vol. 4, Núm. 5
2008
-
Neuregulins and cancer
Clinical Cancer Research, Vol. 14, Núm. 11, pp. 3237-3241